​
​

ARS Pharmaceuticals Stock (NASDAQ:SPRY)

ForecastOwnershipFinancialsChart
ARS Pharmaceuticals by TradingView

Previous Close

$11.75

52W Range

$2.55 - $16.50

50D Avg

$11.17

200D Avg

$8.48

Market Cap

$1.10B

Avg Vol (3M)

$1.03M

Beta

0.77

Div Yield

-

SPRY Company Profile

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

23

IPO Date

Dec 04, 2020

Website

SPRY Performance

SPRY Financial Summary

Dec 23Dec 22Dec 21
Revenue$30.00K$1.32M$5.51M
Operating Income$-67.52M$-35.52M$-19.45M
Net Income$-54.37M$-33.99M$-20.24M
EBITDA$-67.45M$-35.06M$-19.45M
Basic EPS$-0.57-$-0.22
Diluted EPS$-0.57-$-0.22

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
CUECue Biopharma, Inc.
CFRXContraFect Corporation
CNSPCNS Pharmaceuticals, Inc.
TCRXTScan Therapeutics, Inc.
AVROAVROBIO, Inc.
DRMADermata Therapeutics, Inc.
ANNXAnnexon, Inc.
WVEWave Life Sciences Ltd.
ALLRAllarity Therapeutics, Inc.
IMMXImmix Biopharma, Inc.
INABIN8bio, Inc.
TFFPTFF Pharmaceuticals, Inc.
WINTWindtree Therapeutics, Inc.
CGTXCognition Therapeutics, Inc.
HEPAHepion Pharmaceuticals, Inc.
ZURAZura Bio Limited
PALIPalisade Bio, Inc.